“…Investigators can now make measurements in humans, human-derived cells, or biologic samples that can precisely define person-to-person differences in organelle function, the behavior and abundance of proteins, metabolites, or the level and pattern expression of genes. People are now determining not just the variation in the genome that controls clinical disease but also, more refined "endophenotypes," such as how variation throughout the genome affects the level of expression of genes in the kidney (7,8). As the fast pace of progress in the development of human-derived models, such as induced pluripotent stem cell-derived cells, kidney organoids, and kidneys on chips, continues, we will expand our ability to define phenotypes, including responses to various perturbations, in ways that we cannot with living humans (9,10).…”